190 results on '"Parma G"'
Search Results
2. In-flight Icing: Modeling, Prediction, and Uncertainty
3. Bioprosthetic aortic valve degeneration evaluated by 18F-fluoride PET-TC
4. In-flight Icing: Modeling, Prediction, and Uncertainty
5. 32O 5-year (y) overall survival (OS) with maintenance olaparib (ola) plus bevacizumab (bev) by clinical risk in patients (pts) with newly diagnosed advanced ovarian cancer (AOC) in the phase III PAOLA-1/ENGOT-ov25 trial
6. Association of location of BRCA1 and BRCA2 mutations with benefit from olaparib and bevacizumab maintenance in high-grade ovarian cancer: phase III PAOLA-1/ENGOT-ov25 trial subgroup exploratory analysis
7. Neoadjuvant chemotherapy prior to pelvic exenteration in patients with recurrent cervical cancer: Single institution experience
8. Stroke Work Damping Ratio is Increased in Trained Athletes
9. EPV084/#549 Role of dose-dense neoadjuvant chemotherapy with paclitaxel and carboplatin in locally advanced cervical cancer
10. Arterial-Ventricular Coupling Impairment is Evidenced in Both Normal and Ischemic Subjects by Applying Cluster Analysis
11. 167 Safety and quality of life of first-line maintenance olaparib plus bevacizumab in older patients with advanced ovarian cancer in the PAOLA-1 trial
12. Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
13. Phase II of oral gimatecan in patients with recurrent epithelial ovarian, fallopian tube or peritoneal cancer, previously treated with platinum and taxanes
14. 2148P Venous thromboembolism (VTE) in patients with advanced high grade ovarian carcinoma (aHGOC) receiving PARP inhibitors
15. 2041P The prevalence of hematologic adverse events (HAEs) and myelodysplastic syndrome/acute myeloid leukemia (MDS/AML) in patients (pts) with advanced high grade ovarian carcinoma (aHGOC) receiving PARP inhibitor (PARPi), with or without a germline BRCA pathogenic variant
16. A phase II, randomized trial of neo-adjuvant chemotherapy comparing a three-drug combination of paclitaxel, ifosfamide, and cisplatin (TIP) versus paclitaxel and cisplatin (TP) followed by radical surgery in patients with locally advanced squamous cell cervical carcinoma: the Snap-02 Italian Collaborative Study
17. A Robust 3D Particle Tracking Solver for In-flight Ice Accretion using Arbitrary Precision Arithmetic
18. A prognostic nomogram to predict overall survival in patients with platinum-sensitive recurrent ovarian cancer
19. Temporal trend and risk factors for mother-to-child HIV transmission in Southern Brazil, 2007-2017
20. Arterial-Ventricular Coupling Evaluation in Individuals with Stress-Evidenced Diastolic Dysfunction: A Pilot Study
21. Tumour-infiltrating lymphocytes (TILs) in patients with epithelial ovarian cancer undergoing neoadjuvant chemotherapy: A retrospective study
22. Does the presence of aortopathy in bicuspid aortic valve patients increase the risk of aortopathy in their first degree relatives?
23. Randomized Controlled Trial of Single-Agent Paclitaxel Versus Cyclophosphamide, Doxorubicin, and Cisplatin in Patients With Recurrent Ovarian Cancer Who Responded to First-Line Platinum-Based Regimens
24. RANDOMISED TRIAL COMPARING DOXORUBICIN, PACLITAXEL (AT), VERSUS PACLITAXEL (T), AS SECOND LINE THERAPY FOR ADVANCED OVARIAN CANCER (AOC) PATIENTS IN EARLY PROGRESSION AFTER PLATINUM-BASED CHEMOTHERAPY.
25. Monte Carlo integrated approach to radiological characterization for nuclear facilities decommissioning
26. FRI0361 Pregnancy outcomes and therapy in systemic lupus erythematosus: results from our 30 years’ experience pregnancy clinic
27. PS4:82 Lupus pregnancy: achievements and open issues in the multidisciplinary management
28. Paclitaxel, ifosfamide and cisplatin (TIP) chemotherapy for recurrent or persistent squamous-cell cervical cancer
29. 1018P - Tumour-infiltrating lymphocytes (TILs) in patients with epithelial ovarian cancer undergoing neoadjuvant chemotherapy: A retrospective study
30. Chemotherapy for sex-cord stromal tumors
31. Simple conization and lymphadenectomy for the conservative treatment of stage ib1 cervical cancer
32. First-line chemotherapy in advanced ovarian cancer
33. Consenso uruguayo de síndromes coronarios agudos sin elevación del segmento ST
34. A phase II, randomized trial of neo-adjuvant chemotherapy comparing a three-drug combination of paclitaxel, ifosfamide, and cisplatin (TIP) versus paclitaxel and cisplatin (TP) followed by radical surgery in patients with locally advanced squamous cell cervical carcinoma: the Snap-02 Italian Collaborative Study
35. Does early coronary artery bypass surgery improve survival in non-ST acute myocardial infarction?
36. Serum CA 125 assay at the time of relapse has no prognostic relevance in patients undergoing chemotherapy for recurrent ovarian cancer: a multicenter Italian study
37. Prognostic nomogram to predict progression-free survival in patients with platinum-sensitive recurrent ovarian cancer
38. 296 INVITED Neoadjuvant Chemotherapy in Locally Advanced Cervical Cancer
39. Randomized Phase III Clinical Trial Evaluating Weekly Cisplatin for Advanced Epithelial Ovarian Cancer
40. Phase Ib study of RAD001 (R) with pegylated-liposomal doxorubicin (PLD) in patients with advanced solid tumors.
41. A phase II combination study of bortezomib with pegylated-liposomal doxorubicin in patients with ovarian cancer failing platinum containing regimens
42. Total neuropathy scale items as early predictors of chemotherapy‐induced peripheral neurotoxicity
43. Grading of chemotherapy-induced peripheral neurotoxicity using the Total Neuropathy Scale
44. Paclitaxel, Ifosfamide and Cisplatin (TIP) chemotherapy for recurrent or advanced squamous cell cervical cancer (SCCC)
45. Serum CA125 assay at the time of relapse has no prognostic relevance in patients undergoing chemotherapy for recurrent ovarian cancer: a multicenter Italian study
46. Phase II study of paclitaxel as salvage treatment in advanced endometrial cancer
47. Salvage therapy with ifosfamide and mitoxantrone in advanced ovarian cancer
48. 925 Dose-finding study of taxol (T) and cyclophosphamide (C) in advanced breast cancer (ABC)
49. Central nervous system metastases in patients with ovarian carcinoma
50. Options for Primary Chemotherapy in Advanced Ovarian Cancer: The European Perspective
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.